ImmuCell Corporation (ICCC)

USD 4.43

(-8.66%)

Market Cap (In USD)

39.47 Million

Revenue (In USD)

17.47 Million

Net Income (In USD)

-5.77 Million

Avg. Volume

36.85 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.34-5.82
PE
-
EPS
-
Beta Value
0.567
ISIN
US4525253062
CUSIP
452525306
CIK
811641
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael F. Brigham
Employee Count
-
Website
https://immucell.com
Ipo Date
1987-05-05
Details
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

More Stocks